How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,010 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Non-drug interventions for the treatment of benign prostatic syndrome (BPS)

Non-drug interventions for the treatment of benign prostatic syndrome (BPS) 1 Translation of the key statement of the rapid report Nichtmedikamentöse lokale Verfahren zur Behandlung des benignen Prostatasyndroms – Aktualisierung (Version 1.1; Status: 2 August 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N15-07 Non (...) -drug local procedures for treatment of benign prostatic syndrome – update 1 Key statement of rapid report N15-07 Version 1.1 Non-drug local procedures for treatment of BPS – update 2 August 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Non-drug local procedures for treatment of benign prostatic syndrome – update Commissioning agency: Federal Joint Committee Commission awarded on: 25

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

122. Re: Treatment Satisfaction and Clinically Meaningful Symptom Improvement in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia: Secondary Results from a 6-Month, Randomized, Double-Blind Study Compari (Abstract)

Re: Treatment Satisfaction and Clinically Meaningful Symptom Improvement in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia: Secondary Results from a 6-Month, Randomized, Double-Blind Study Compari 27628819 2018 07 30 2018 12 02 1527-3792 196 4 2016 10 The Journal of urology J. Urol. Re: Treatment Satisfaction and Clinically Meaningful Symptom Improvement in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary (...) to Benign Prostatic Hyperplasia: Secondary Results from a 6-Month, Randomized, Double-Blind Study Comparing Finasteride plus Tadalafil with Finasteride plus Placebo. 1220-1 10.1016/j.juro.2016.07.033 S0022-5347(16)30819-9 Kaplan Steven A SA eng Journal Article Comment 2016 07 15 United States J Urol 0376374 0022-5347 57GNO57U7G Finasteride 742SXX0ICT Tadalafil AIM IM Int J Urol. 2015 Jun;22(6):582-7 25827166 Double-Blind Method Finasteride Humans Lower Urinary Tract Symptoms Male Personal Satisfaction

2018 The Journal of urology Controlled trial quality: predicted high

123. Re: WATER: A Double-blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. (Abstract)

Re: WATER: A Double-blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. 29650236 2018 12 18 2018 12 18 1873-7560 74 2 2018 08 European urology Eur. Urol. Re: WATER: A Double-blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. 233 S0302-2838(18)30244-6 10.1016/j.eururo.2018.03.026 Madersbacher Stephan S Department of Urology, Kaiser Franz Josef (...) Hospital, Sigmund Freud Private University, Vienna, Austria. Electronic address: madersbacher@hotmail.com. eng Journal Article Comment 2018 04 09 Switzerland Eur Urol 7512719 0302-2838 059QF0KO0R Water IM J Urol. 2018 May;199(5):1252-1261 29360529 Double-Blind Method Humans Male Prostatic Hyperplasia surgery Transurethral Resection of Prostate Water 2018 03 03 2018 03 24 2018 4 14 6 0 2018 12 19 6 0 2018 4 14 6 0 ppublish 29650236 S0302-2838(18)30244-6 10.1016/j.eururo.2018.03.026

2018 European Urology Controlled trial quality: predicted high

124. Randomized Controlled Trial of Aquablation vs. Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-Year Outcomes. (Abstract)

Randomized Controlled Trial of Aquablation vs. Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-Year Outcomes. To report 1-year safety and efficacy outcomes after either Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) METHODS: This double-blinded, multicenter prospective randomized controlled trial assigned 181 patients with BPH-related moderate-to-severe (...) lower urinary tract symptoms to either electrocautery-based prostate resection (TURP) or Aquablation. Efficacy endpoints included reduction in International Prostate Symptom Score and improvement in uroflow parameters. The primary safety endpoint was the occurrence of Clavien-Dindo persistent grade 1 or grade 2 or higher complications.BPH symptom score improvements were similar across groups with 12-month reduction of 15.1 points after TURP or Aquablation. In both groups, mean maximum urinary flow

2018 Urology Controlled trial quality: predicted high

125. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs. (Abstract)

Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs. Benign prostatic hyperplasia (BPH) is characterized by an enlargement of the prostate accompanied by an increase in prostatic blood perfusion and vascularization. The most indicated treatment is to perform orchiectomy, however, medical treatment with finasteride can be an option for breeding dogs or elderly animals with a critical health status. In dogs, the influence of medical treatment (...) on prostatic hemodynamics is still unknown. Therefore, this study aimed to evaluate the effects of benign prostatic hyperplasia and finasteride therapy on hemodynamic and vascular features of the canine prostate. For this purpose, twenty dogs of different breeds, body weights (10-30 kg) and ages (5-13 years) were used, assigned for: Healthy-non treated group (n = 5), BPH-non treated group (n = 5), Healthy-finasteride treated group (n = 5) and BPH-finasteride treated group (n = 5). Dogs that presented

2018 Theriogenology Controlled trial quality: uncertain

126. Comparison of 532 nm Greenlight HPS laser with 980 nm diode laser vaporization of the prostate for the treatment of lower urinary tract symptom secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

Comparison of 532 nm Greenlight HPS laser with 980 nm diode laser vaporization of the prostate for the treatment of lower urinary tract symptom secondary to benign prostatic hyperplasia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate

2020 PROSPERO

127. Radiation dose of prostatic artery embolisation for benign prostatic hyperplasia: protocol for a systematic review

Radiation dose of prostatic artery embolisation for benign prostatic hyperplasia: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2020 PROSPERO

128. Prostatic Artery Embolization for Benign Prostatic Hyperplasia

Prostatic Artery Embolization for Benign Prostatic Hyperplasia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2020 PROSPERO

129. Meta-analysis and Systematic Review of Intermediate term follow up of Prostatic Urethral Lift for Benign Prostatic Hyperplasia

Meta-analysis and Systematic Review of Intermediate term follow up of Prostatic Urethral Lift for Benign Prostatic Hyperplasia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

130. 5-year long-term efficacy of 120-W GreenLight photoselective vaporization of the prostate for benign prostate hyperplasia. Full Text available with Trip Pro

5-year long-term efficacy of 120-W GreenLight photoselective vaporization of the prostate for benign prostate hyperplasia. To investigate 5-year long-term postoperative efficacy in benign prostate hyperplasia (BPH) following 120-W GreenLight high-performance system photoselective vaporization of the prostate (HPS-PVP).This was a retrospective study of surgical outcomes in 159 men who underwent HPS-PVP and were followed over 60 months postoperatively. Definitions of treatment success were (...) established based on the following three variables: international prostate symptom scores (IPSS), maximum flow rates (Qmax), and quality of life scores QoL). Logistic regression analyses were performed to determine predictors of the postoperative success.Postoperative IPSS/QoL, Qmax and post-voided residual urine volume were significantly improved after HPS-PVP. Postoperative Prostate specific antigen and prostate volume were also well reduced and sustained for 5 years. The postoperative success rate

2017 PLoS ONE

131. 3-year treatment outcomes of water vapor thermal therapy (Rezūm System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. (Abstract)

3-year treatment outcomes of water vapor thermal therapy (Rezūm System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. We evaluated the long-term outcomes of treatment of lower urinary tract symptoms due to benign prostatic hyperplasia to compare a 1-time water vapor thermal therapy procedure with daily medical therapy in cohorts from the MTOPS (Medical Therapy (...) of Prostatic Symptoms) study.Results in the treatment arm of a randomized, controlled trial of thermal therapy using the Rezūm® System were compared to MTOPS subjects treated with doxazosin and/or finasteride. Evaluations were restricted to medical therapy subjects, representing 1,140 of the original 3,047 (37.4%), with a prostate volume of 30 to 80 cc and an International Prostate Symptom Score of 13 or greater to include men who met key criteria of the Rezūm and MTOPS trials. Outcomes were compared

2018 Journal of Urology Controlled trial quality: uncertain

132. Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial. (Abstract)

Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial. To explore efficacy and safety of Botulinum Neurotoxin Type A (BoNT-A) prostatic injection in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperperplasia.A phase 3 multicenter open-labeled study randomised patients to receive BoNT-A prostatic injection (...) or optimized medical therapy. BoNT-A injection consisted in trans-rectal injections of 200 UI in the transitional zone of the prostate. Optimal medical therapy consisted in oral medication with any drug patented for LUTS. One month (M1) after randomisation patients in the BoNT-A group were asked to stop any medical therapy related to LUTS. The main judgment criterion was the IPSS score at M4. Per-protocol analysis was performed with a non-inferiority hypothesis (ΔIPSS < 3).127 patients were randomised

2018 World journal of urology Controlled trial quality: uncertain

133. WATER - A Double-Blind Randomized Controlled Trial of Aquablation vs. Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. (Abstract)

WATER - A Double-Blind Randomized Controlled Trial of Aquablation vs. Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. We compared the safety and efficacy of Aquablation and transurethral prostate resection for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.In a double-blind, multicenter, prospective, randomized, controlled trial 181 patients with moderate to severe lower urinary tract symptoms related to benign prostatic (...) hyperplasia underwent transurethral prostate resection or Aquablation. The primary efficacy end point was the reduction in International Prostate Symptom Score at 6 months. The primary safety end point was the development of Clavien-Dindo persistent grade 1, or 2 or higher operative complications.Mean total operative time was similar for Aquablation and transurethral prostate resection (33 vs 36 minutes, p = 0.2752) but resection time was lower for Aquablation (4 vs 27 minutes, p <0.0001). At month 6

2018 Journal of Urology Controlled trial quality: predicted high

134. Impact of 5α-Reductase Inhibitors and α-Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality. Full Text available with Trip Pro

Impact of 5α-Reductase Inhibitors and α-Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality. To investigate the use of 5α-reductase inhibitors (5ARIs) and α-blockers among men with benign prostatic hyperplasia (BPH) in relation to prostate cancer (PCa) incidence, severity and mortality.A retrospective 20-year cohort study in men residing in Saskatchewan, aged 40-89 years, with a BPH-coded medical claim between 1995 and 2014, was conducted. Cox proportional

2018 BJU international

135. Bipolar plasma enucleation of the prostate vs. open prostatectomy in large benign prostatic hyperplasia: a single centre 3-year comparison. (Abstract)

Bipolar plasma enucleation of the prostate vs. open prostatectomy in large benign prostatic hyperplasia: a single centre 3-year comparison. Aim of our study is to compare the surgery outcomes and safety of button bipolar enucleation of the prostate vs. open prostatectomy in patients with large prostates (> 80 g) in a single-centre cohort study.All patients with lower urinary tract symptoms due to benign prostatic enlargement undergoing button bipolar enucleation of the prostate (B-TUEP) or open (...) prostatectomy (OP) between May 2012 and December 2013 were enroled in our study. Data on clinical history, physical examination, urinary symptoms, erectile function, uroflowmetry and prostate volume were collected at 0, 1, 3, 6, 12, 24 and 36 months. Early and long-term complications were recorded.Overall, 240 patients were enroled. Out of them 111 patients (46%) performed an OP and 129 patients (54%) performed a B-TUEP. In terms of efficacy, both procedures showed durable results at three years

2018 Prostate cancer and prostatic diseases

136. Temporal trend in incidental prostate cancer detection at surgery for benign prostatic hyperplasia. Full Text available with Trip Pro

Temporal trend in incidental prostate cancer detection at surgery for benign prostatic hyperplasia. To assess changes in the rate of incidental prostate cancer (PCa) after benign prostatic hyperplasia (BPH) surgery over the last decade.We identified 1177 patients surgically treated for BPH (open prostatectomy, transurethral resection or holmium laser enucleation [HoLEP] of the prostate) in 2007-2016 at a single European academic center. Local polynomial regression was used to explore changes (...) in the rate of preoperative prostate biopsies (OR: 0.83; 95%CI: 0.79-0.88, P < .0001). Patients undergoing a preoperative biopsy showed a lower risk of being diagnosed with PCa after surgery (OR: 0.29; 95% CI: 0.12, 0.72 P = .007). Patients treated with HoLEP had a higher chance of incidental PCa detection (OR: 2.28; 95%CI: 1.30-4.00; P = .004), although this may be related to the significantly higher number of HoLEP performed over the last years.The increased rate of low-risk PCa detected after BPH

2018 Urology

137. Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer. (Abstract)

Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer. Long non-coding RNAs (lncRNAs) have recently appeared as new players in cancer biology. Recently, a number of new prostate cancer-associated lncRNAs has been listed via RNA-seq approach by Mitranscriptome project. By analyzing this data we chose four lncRNAs (Prcat17.3, Prcat38, Prcat47, and Cat2184.4) and evaluated their expressions and their abilities (...) to discriminate prostate tumors from benign prostate hyperplasia (BPH).Fresh Prostate tissue samples (30 BPH, and 30 tumor samples) and urine samples (19 BPH, and 19 tumor samples) were collected and their total RNA extracted for cDNA syntheses. The expression of candidate lncRNAs was assessed by the real-time PCR technique.Our data revealed that the expression levels of PRCAT17.3 (P < 0.0001) and PRCAT38 (P < 0.0002) were significantly upregulated in human prostate cancer tissues, compared to BPH ones

2018 Prostate

138. Nerve growth factor levels are associated with overactive bladder symptoms and long-term treatment outcome after transurethral resection of the prostate in patients with benign prostate hyperplasia. (Abstract)

Nerve growth factor levels are associated with overactive bladder symptoms and long-term treatment outcome after transurethral resection of the prostate in patients with benign prostate hyperplasia. We investigated changes in urinary nerve growth factor in patients with benign prostatic hyperplasia after transurethral prostate resection. We also assessed the association between nerve growth factor and changes of overactive bladder symptoms and long-term treatment outcomes after surgery.This (...) was a prospective study of 178 patients at Peking University People's Hospital with benign prostatic hyperplasia between January 2011 and January 2013. Urinary nerve growth factor levels were determined preoperatively using a commercial enzyme-linked immunosorbent assay kit. We also determined prostate volume, I-PSS (International Prostate Symptom Score), quality of life, OABSS (Overactive Bladder Symptom Score), ultrasound estimated post-void residual urine and urodynamics before surgery. Urinary nerve growth

2018 Journal of Urology

139. Comparision of transurethral plasmakinetic enucleation and Holmium laser enucleation of the prostate for benign prostatic hyperplasia: a meta-analysis

Comparision of transurethral plasmakinetic enucleation and Holmium laser enucleation of the prostate for benign prostatic hyperplasia: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

140. Prostatic stromal inflammation is associated with bladder outlet obstruction in patients with benign prostatic hyperplasia. (Abstract)

Prostatic stromal inflammation is associated with bladder outlet obstruction in patients with benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH) is a common urologic disease in older men. Prostatic inflammation research has focused on the magnitude of inflammation; its location has received little attention. We investigated whether the anatomic location of prostatic inflammation is related to the severity of lower urinary tract symptoms (LUTS), measured subjectively (...) and objectively.We retrospectively analyzed hematoxylin+eosin-stained tissue specimens from 179 BPH patients who underwent transurethral resection of the prostate (TURP) or holmium laser enucleation of the prostate (HoLEP). Chronic prostatic inflammation was assessed by the grade (lymphocyte density), extent (lymphocyte distribution), and location of inflammation. Each inflammation-finding type was evaluated in relation to these clinical parameters: age, prostate volume, prostate-specific antigen (PSA) value

2018 Prostate

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>